Skip to main content

mazdutide

mazdutide: 4 clinical trials tracked.

mazdutide evidence translation

What we can confirm

4 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about mazdutide, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (4)

Short-term Mazdutide Plus Lifestyle Intervention Versus Placebo for Pre-hepatectomy Prehabilitation in Living Liver Donors With MASLD: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial

NCT07718126Registry updated 2026-07-21·Phase 2/Phase 3
Not yet recruiting

Primary endpoint: Proportion of Participants Achieving Resolution of MASLD Without Worsening of Liver Fibrosis (ROM)

InterventionalRandomizedtriple60 targetStarted 2026-09Completion 2028-083 sites · ChinaWest China Hospital

A Multicenter, Randomized, Open-label, Parallel-controlled, Phase 3 Study to Compare the Efficacy and Safety of HDM1005 Versus Mazdutide in Subjects With T2DM Inadequate Glycemic Control by Metformin Monotherapy or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor

NCT07417306Registry updated 2026-02-18·Phase 3
Not yet recruiting

Primary endpoint: Change from baseline in Hemoglobin A1c (HbA1c)

InterventionalRandomizedopen912 targetStarted 2026-03Completion 2027-121 site · ChinaHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

A Phase 2, Double-Blind, Proof of Concept Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder

NCT06817356Registry updated 2026-07-16·Phase 2
Completed

Primary endpoint: Behaviors Associated with Alcohol Use Disorder (AUD) as Assessed by the Timeline Followback Method

InterventionalRandomizeddouble308 enrolledStarted 2025-02Completion 2026-0525 sites · United StatesEli Lilly and Company

A Phase 2, Parallel-Group, Double-Blind, 4-Arm Study to Investigate Weight Management With LY3305677 Compared With Placebo and in Adult Participants With Obesity or Overweight

NCT06124807Registry updated 2026-04-21·Phase 2
Completed

Primary endpoint: Percent Change From Baseline in Body Weight at Week 32

InterventionalRandomizeddouble179 enrolledStarted 2023-11Completion 2025-0729 sites · United StatesEli Lilly and Company